
zzso is a potent and selective inhibitor of vascular zzso growth factor zzso zzso zzso zzso A previous clinical trial in the zzso and USA indicated that zzso at the maximum tolerated dose of zzso zzso showed an zzso activity in patients with zzso cell zzso This Japanese phase I study was designed to determine the recommended phase II dose of zzso for Japanese zzso secondary objectives included zzso profiles and preliminary zzso Daily treatment with zzso in a zzso cycle was examined in nine Japanese patients with advanced solid tumors in the 3 + 3 design zzso 1, zzso zzso Level 2, zzso zzso No zzso toxicity was observed throughout the study, and the maximum tolerated dose was not zzso The most commonly observed drug-related adverse events were zzso zzso zzso zzso stimulating hormone increase, and with severity grade zzso zzso skin reaction, hypertension, and zzso Those adverse events were generally zzso and mostly resolved within the zzso evaluation zzso zzso exposure to zzso resulted in zzso of more than zzso zzso zzso of plasma zzso and decrease of plasma zzso and zzso were observed 1-3 weeks after zzso zzso Although no complete or partial response was observed, long-term stable disease continuing more than 170 days was observed in three zzso cell zzso patients who had failed prior zzso zzso In conclusion, zzso zzso of zzso in a zzso setting was tolerable in Japanese patients, and was recommended for further clinical trials in the Japanese zzso Clinical trial Registration zzso zzso 

